BeOne Medicines (ONC) Capital Expenditures (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Capital Expenditures of $43.2 million for Q1 2026, down 27.93% year-over-year from $60.0 million in Q1 2025, and up 147.51% quarter-over-quarter from -$91.0 million in Q4 2025.
BeOne Medicines (ONC) Capital Expenditures (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Capital Expenditures for 12 consecutive years, with $43.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 27.93% year-over-year to $43.2 million; the TTM figure through Mar 2026 stood at $40.5 million (up 254.35% YoY), while the FY2025 annual figure was $57.3 million, down 18.53% from the prior year.
- Capital Expenditures advanced to $43.2 million in Q1 2026 per ONC's latest filing, from -$91.0 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $183.0 million in Q2 2023 and bottomed at -$139.4 million in Q3 2023.
- Historically, Capital Expenditures has averaged $34.6 million across 5 years, with a median of $43.2 million in 2026.
- Annual changes were most pronounced in 2023 — Capital Expenditures jumped 1251.36% — and 2025, when it tumbled 1719.59%.
- BeOne Medicines' Capital Expenditures stood at $121.4 million in 2022, then sank by 113.03% to -$15.8 million in 2023, then jumped by 68.35% to -$5.0 million in 2024, then sank by 1719.59% to -$91.0 million in 2025, then surged by 147.51% to $43.2 million in 2026.
- Business Quant data shows ONC's Capital Expenditures at $43.2 million in Q1 2026, -$91.0 million in Q4 2025, and $48.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.02 Mn |
| Jun 30, 2026 | 25.02 Mn |
| Mar 31, 2026 | 43.25 Mn |
| Mar 31, 2026 | 43.25 Mn |
| Dec 31, 2025 | -91.03 Mn |
| Dec 31, 2025 | -91.03 Mn |
| Sep 30, 2025 | 48.08 Mn |
| Sep 30, 2025 | 48.08 Mn |
| Jun 30, 2025 | 40.22 Mn |
| Jun 30, 2025 | 40.22 Mn |
| Mar 31, 2025 | 60.01 Mn |
| Mar 31, 2025 | 60.01 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Sep 30, 2024 | -40.25 Mn |
| Sep 30, 2024 | -40.25 Mn |
| Jun 30, 2024 | -41.01 Mn |
| Jun 30, 2024 | -41.01 Mn |
| Mar 31, 2024 | 156.58 Mn |
| Mar 31, 2024 | 156.58 Mn |